Jeffrey Wolf
About Jeffrey Wolf
Jeffrey Wolf, J.D., age 62, has served on Theriva Biologics’ Board since 2006 and is deemed independent under NYSE American rules; he currently chairs the Audit Committee and sits on the Compensation and Nominations Committees . He holds an MBA from Stanford, a J.D. from NYU School of Law, and a B.A. in Economics (with honors) from the University of Chicago; his background spans founding and leading multiple biomedical ventures and a venture firm .
Past Roles
| Organization | Role | Tenure | Committees/Impact |
|---|---|---|---|
| Seed‑One Ventures, LLC | Managing Director | Jun 1997–Mar 2011 | Launched and grew healthcare companies |
| Avigen | Co‑founder and Director | Not disclosed | Early gene therapy company; foundational experience |
| TyRx Pharma | Co‑founder and Chairman | Not disclosed | Bio‑compatible polymers; leadership role |
| Elusys Therapeutics | Founder/executive (startup) | Not disclosed | Developed ANTHIM (FDA‑approved anthrax antitoxin) |
External Roles
| Organization | Role | Tenure | Notes |
|---|---|---|---|
| Scorpius Holdings, Inc. (public) | Chief Executive Officer and Chairman of the Board | CEO/Chair since Apr 2010; founded Aug 2008 | Public CDMO; ongoing leadership |
Board Governance
| Item | Disclosure |
|---|---|
| Independence | Independent director; Board majority independent excluding CEO/CFO |
| Committees | Audit (Chair), Compensation (Member), Nominations (Member) |
| Financial Expertise | Audit Committee Financial Expert; financially literate |
| Attendance | Each director attended ≥75% of Board and committee meetings in 2024 |
| Board leadership | Independent Chairman (Kraws); separation of Chair and CEO |
| Clawback | Board‑adopted clawback policy for performance‑based comp |
| Anti‑hedging/pledging | Company prohibits hedging and pledging of stock |
Fixed Compensation
| Component (2024) | Amount |
|---|---|
| Fees earned or paid in cash (Wolf) | $70,750 |
| Option awards (grant‑date fair value) | $0 |
| Other compensation | $0 |
| Total | $70,750 |
Director cash compensation policy (2024):
- Annual cash retainer: $47,000 (non‑employee director)
- Committee membership fees: Audit $7,500; Compensation $5,000; Nominations $3,750
- Committee chair fees: Audit $15,000; Compensation $10,000; Nominations $7,500
- Independent Chairman retainer: $154,000 (role specific, not applicable to Wolf)
- Compensation Committee relied on Meridian report (Dec 2023) for setting 2024 director pay
Performance Compensation
| Equity element | Detail |
|---|---|
| Non‑executive director option grants (awarded in 2025 for 2024 service) | Group total: 75,000 options to all current non‑executive directors; individual allocations not disclosed |
| Plan constraints | Non‑employee director annual equity cap: 250,000 shares under the 2020 Plan |
No performance metrics (TSR, revenue, ESG) are tied to director compensation; director pay is retainer/committee fee‑based with periodic equity grants, and no meeting fees are disclosed .
Other Directorships & Interlocks
| Board/Role | Potential interlock/conflict | Status |
|---|---|---|
| Scorpius Holdings, Inc. (CEO/Chair) | CDMO services could overlap sectorally | Company discloses no related‑party transactions involving Wolf; RPT section cites only compensation to CEO’s spouse |
Compensation Committee interlocks: The proxy reports no interlocks involving the Company’s executive officers in 2024; not specific to Wolf but relevant to governance context .
Expertise & Qualifications
- Degrees: MBA (Stanford), J.D. (NYU), B.A. Economics with honors (University of Chicago)
- Domain: Founding/financing biomedical companies; R&D oversight; legal/business acumen
- Audit acumen: Audit Committee Financial Expert designation
Equity Ownership
| As‑of | Shares Beneficially Owned | % of Outstanding | Notes |
|---|---|---|---|
| Record date July 8, 2025 (Annual Meeting) | 19,451* | <1% | Includes 19,451 options exercisable within 60 days |
| Record date Oct 30, 2025 (Special Meeting) | 25,701* | <1% | Includes 25,701 options exercisable within 60 days |
- Anti‑hedging/anti‑pledging policy in force for directors .
- Outstanding director option counts shown separately: Wolf held 11,118 option awards outstanding as of Dec 31, 2024 (disclosure basis differs from “exercisable within 60 days”) .
- Ownership guidelines for directors are not disclosed; equity plan 2020 limits apply .
Governance Assessment
Strengths:
- Independent director, Audit Chair, and Audit Committee Financial Expert; governance structure separates Chair and CEO .
- Adequate engagement (≥75% attendance in 2024) .
- No related‑party transactions disclosed for Wolf; robust insider trading policy (anti‑hedging/pledging) and clawback regime .
Signals to monitor:
- Ownership alignment appears limited (beneficial ownership <1% at both 2025 record dates), though periodic equity grants to non‑executive directors help alignment over time .
- External leadership at Scorpius (CEO/Chair) warrants ongoing oversight for potential conflicts if Theriva engages CDMO services; no related‑party dealings are disclosed to date .
Say‑on‑pay and shareholder feedback:
- Prior say‑on‑pay (2022) received ~97% support, indicating broad investor approval of compensation practices at that time .
- Board recommends a three‑year frequency for future say‑on‑pay votes; stockholders will vote on frequency in 2025 .
Citations: **[894158_0001104659-25-066731_tm2520034-2_def14a.htm:10]** **[894158_0001104659-25-066731_tm2520034-2_def14a.htm:14]** **[894158_0001104659-25-066731_tm2520034-2_def14a.htm:15]** **[894158_0001104659-25-066731_tm2520034-2_def14a.htm:17]** **[894158_0001104659-25-066731_tm2520034-2_def14a.htm:18]** **[894158_0001104659-25-066731_tm2520034-2_def14a.htm:19]** **[894158_0001104659-25-066731_tm2520034-2_def14a.htm:20]** **[894158_0001104659-25-066731_tm2520034-2_def14a.htm:22]** **[894158_0001104659-25-066731_tm2520034-2_def14a.htm:23]** **[894158_0001104659-25-066731_tm2520034-2_def14a.htm:30]** **[894158_0001104659-25-066731_tm2520034-2_def14a.htm:37]** **[894158_0001104659-25-066731_tm2520034-2_def14a.htm:44]** **[894158_0001104659-25-066731_tm2520034-2_def14a.htm:48]** **[894158_0001104659-25-066731_tm2520034-2_def14a.htm:54]** **[894158_0001104659-25-066731_tm2520034-2_def14a.htm:55]** **[894158_0001104659-25-109200_tm2529873d2_def14a.htm:11]** **[894158_0001104659-25-066731_tm2520034-2_def14a.htm:13]**